Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

News Oculis Holding AG

Equities

OCS

CH1242303498

Real-time Estimate Cboe BZX
Other stock markets
 03:23:59 2024-06-06 pm EDT 		5-day change 1st Jan Change
11.98 USD +0.21% Intraday chart for Oculis Holding AG +0.17% +6.41%
May. 30 Oculis Holding AG Announces Board and Committee Appointments CI
May. 30 Oculis Holding AG announced a financing transaction CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GL
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
GL
Oculis Holding AG Announces Board and Committee Appointments
CI
Oculis Holding AG announced a financing transaction
CI
Oculis Holding - Increase in share capital
AQ
Oculis updates share capital for its existing at-the-market offering program
GL
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K
PU
Oculis : Form 6-K
PU
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
GL
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
AQ
Oculis Publishes Invitation to the Annual General Meeting
GL
Oculis to Present at Bank of America Global Healthcare Conference
AQ
Oculis Publishes Invitation to the Annual General Meeting
AQ
H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating
MT
Oculis Holding AG(NasdaqGM:OCS) added to OMX Nordic All-Share Index
CI
Oculis Completes $59 Million Direct Offering of Shares
MT
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
GL
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
AQ
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCS Stock
  4. News Oculis Holding AG